Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Update: 2025-09-25

Description

Join Professor Iain McInnes for the latest episode of Discussing RA on The Immune-Mediated Inflammatory Disease Forum. In this episode, he highlights two papers: risk of MACE, VTE, and malignancies in patients with RA or UC treated with filgotinib and frequency of reporting of MACE, MI, and stroke between JAKis and anti-TNFα.

Comments

In Channel

Discussing PsA: Comparative effectiveness of biologic and targeted therapies in PsA: Insights from PARWCH and KEEPsAKE studies

2025-10-0918:31

Author Interview: Doctor David Kellner, September 2025

2025-10-0222:44

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

2025-09-2508:44

Discussing axSpA: Comparative real-world effectiveness of biologic and targeted therapies in axSpA

2025-09-1820:52

Discussing RA: Efficacy and safety of upadacitinib for patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis

2025-09-0407:41

Author Interview: Doctor Rodrigo Garcia‑Salinas, August 2025

2025-08-2828:57

Author Interview: Doctor Martin Schaefer and Professor Anja Strangfeld, July 2025

2025-08-1445:23

Discussing PsA: Post hoc analyses on secukinumab and deucravacitinib from Phase 2 and 3 trials

2025-08-0717:45

Discussing RA: Comparative outcomes of JAK inhibition and TNF blockade vs dual JAK–ROCK targeting

2025-07-3113:24

Discussing axSpA: Secukinumab treatment outcomes on sustained remission and skeletal health in axSpA

2025-07-1016:44

Difficult-to-treat disease in Rheumatology Podcast Professors Iain McInnes and Peter Nash

2025-07-0341:27

EULAR 2025 Review Podcast

2025-07-0201:05:19

Discussing RA: Impact of TOF on BMI, UPA monotherapy in MTX-IRs, and JAKis vs TNFis treatment

2025-06-2615:20

EULAR 2025 Highlights: Day 4

2025-06-1403:25

EULAR 2025 Highlights: Day 3

2025-06-1302:36

Discussing PsA: Real-world data on biologic switching and the development of EMMs

2025-06-1223:11

EULAR 2025 Highlights: Day 2

2025-06-1204:39

EULAR 2025 Highlights: Day 1

2025-06-1104:03

EULAR 2025 Preview Podcast

2025-06-0925:23

Discussing RA: MACE in RA, data from the "JAK-pot" study, and combination therapy in MTX-IR RA

2025-06-0510:25

00:00

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

The Immune-Mediated Inflammatory Disease Forum

#box-pro-ellipsis-176078936939740{-webkit-line-clamp:2;}Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases

The Immune-Mediated Inflammatory Disease Forum

Discussing RA: Safety and vaccine immunogenicity of upadacitinib across immune-mediated diseases